Roche's surging diagnostics arm scored a major win this week, gaining FDA approval what is being billed as the first companion diagnostic meant to detect a specific mutation connected to metastatic non-small cell lung cancer.
A U.K. startup is partnering with a Japanese company in what has become an increasingly important focus for diagnostics developers: tests that can spot lung cancer in its earliest stages when there is a chance to beat it back.
CytRx has decided to dump a Phase IIb lung cancer study for the number-two drug program in the pipeline after the monitoring committee concluded that the trial was unlikely to find any improvement in progression-free survival compared to standard treatments.
Call it biomarker repurposing. Researchers have identified a compound produced by the body that can flag smokers at increased risk for lung cancer--a substance long used to gauge liver function.
An early snapshot of preliminary data from a midstage study of an experimental lung cancer drug at a Karolinska Development portfolio company offered an encouraging outline of its initial direction, persuading investigators to wrap enrollment earlier than initially planned as it completes the last leg of the trial.
The FDA has opened the inside track to Novartis' experimental lung cancer drug, which gained "Breakthrough Therapy" designation that speeds the development and review schedules for new treatments. The Swiss drug giant ($NVS) plans to file for approval the drug, now in mid-stage clinical trials, in early 2014.
Allegro Diagnostics claims to have successfully reached its primary endpoint in the first of two massive clinical trials for its BronchoGen lung cancer genomic diagnostic, putting the test on track for a late 2013 launch--a bit later than initially projected.
Endocyte's diagnostic imaging agent etarfolatide is getting the job done in ongoing clinical studies. Researchers say they proved it can properly identify ovarian cancer and non-small lung cancer patients who could benefit the most from a particular kind of drug.
Six months after emerging from stealth mode, North Carolina startup GeneCentric is pursuing $2 million in new funding to support the rollout of a targeted lung cancer molecular diagnostic test.
California-based Genelux helmed a first-in-man trial of its new mesothelioma treatment at Memorial Sloan-Kettering Cancer Center in New York.